MA28717B1 - Traitement d'infections fongiques - Google Patents

Traitement d'infections fongiques

Info

Publication number
MA28717B1
MA28717B1 MA29450A MA29450A MA28717B1 MA 28717 B1 MA28717 B1 MA 28717B1 MA 29450 A MA29450 A MA 29450A MA 29450 A MA29450 A MA 29450A MA 28717 B1 MA28717 B1 MA 28717B1
Authority
MA
Morocco
Prior art keywords
treatment
fungal infections
antibody
composition
posaconazole
Prior art date
Application number
MA29450A
Other languages
English (en)
Inventor
James Peter Burnie
Ruth Christine Matthews
Original Assignee
Neutec Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neutec Pharma Ltd filed Critical Neutec Pharma Ltd
Publication of MA28717B1 publication Critical patent/MA28717B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/14—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from fungi, algea or lichens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
MA29450A 2004-04-23 2006-11-13 Traitement d'infections fongiques MA28717B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0409077.5A GB0409077D0 (en) 2004-04-23 2004-04-23 Treatment of fungal infections

Publications (1)

Publication Number Publication Date
MA28717B1 true MA28717B1 (fr) 2007-07-02

Family

ID=32344282

Family Applications (1)

Application Number Title Priority Date Filing Date
MA29450A MA28717B1 (fr) 2004-04-23 2006-11-13 Traitement d'infections fongiques

Country Status (29)

Country Link
US (1) US7785571B2 (fr)
EP (3) EP2044954A1 (fr)
JP (1) JP2007533716A (fr)
KR (1) KR20080024944A (fr)
CN (1) CN1946424A (fr)
AT (1) ATE424846T1 (fr)
AU (1) AU2005235339B2 (fr)
BR (1) BRPI0510052A (fr)
CA (1) CA2564137A1 (fr)
CY (1) CY1109121T1 (fr)
DE (1) DE602005013197D1 (fr)
DK (1) DK1737488T3 (fr)
EC (1) ECSP067022A (fr)
ES (1) ES2322171T3 (fr)
GB (1) GB0409077D0 (fr)
HR (1) HRP20090261T1 (fr)
IL (1) IL178565A0 (fr)
MA (1) MA28717B1 (fr)
MX (1) MXPA06012256A (fr)
NO (1) NO20065246L (fr)
NZ (1) NZ550450A (fr)
PL (1) PL1737488T3 (fr)
PT (1) PT1737488E (fr)
RU (1) RU2380116C2 (fr)
SG (1) SG152269A1 (fr)
SI (1) SI1737488T1 (fr)
TN (1) TNSN06339A1 (fr)
WO (1) WO2005102386A1 (fr)
ZA (1) ZA200608767B (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100113355A1 (en) 2007-04-27 2010-05-06 Naresh Chennamsetty Novel antibody molecules and nucleic acids binding to fungal stress protein hsp90
EP2743699A4 (fr) * 2011-08-12 2015-04-08 Nat Inst Infectious Diseases Méthode pour le test, la prévention et le traitement d'une maladie infectieuse par aspergillus fumigatus, et composition
CN111116743B (zh) * 2018-10-30 2022-01-28 迈威(上海)生物科技股份有限公司 Hsp90抗体及其在抗真菌感染中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8915019D0 (en) 1989-06-30 1989-08-23 Matthews Ruth C Medicaments
RU2073512C1 (ru) * 1995-03-21 1997-02-20 Саратовская научно-исследовательская ветеринарная станция Способ лечения аспергиллеза у кроликов
US5952300A (en) * 1996-04-19 1999-09-14 Merck & Co., Inc. Antifungal compositions
GB0008305D0 (en) 2000-04-06 2000-05-24 Neutec Pharma Plc Treatment of fungal infections
RU2188019C1 (ru) * 2001-06-13 2002-08-27 Открытое акционерное общество "Биосинтез" Фармацевтическая композиция, обладающая противогрибковой активностью, и способ ее получения
MXPA05003124A (es) 2002-09-23 2005-06-22 Schering Corp Uso de posaconazol para el tratamiento de infecciones fungales.

Also Published As

Publication number Publication date
US7785571B2 (en) 2010-08-31
US20080095778A1 (en) 2008-04-24
DK1737488T3 (da) 2009-07-06
CA2564137A1 (fr) 2005-11-03
HK1100320A1 (en) 2007-09-14
BRPI0510052A (pt) 2007-10-16
MXPA06012256A (es) 2007-06-15
AU2005235339B2 (en) 2010-11-25
EP1737488B1 (fr) 2009-03-11
PT1737488E (pt) 2009-05-11
RU2006141354A (ru) 2008-05-27
ECSP067022A (es) 2007-02-28
EP2044954A1 (fr) 2009-04-08
GB0409077D0 (en) 2004-05-26
ATE424846T1 (de) 2009-03-15
PL1737488T3 (pl) 2009-08-31
CN1946424A (zh) 2007-04-11
ZA200608767B (en) 2008-06-25
SG152269A1 (en) 2009-05-29
AU2005235339A1 (en) 2005-11-03
IL178565A0 (en) 2007-02-11
NZ550450A (en) 2009-02-28
NO20065246L (no) 2006-11-15
JP2007533716A (ja) 2007-11-22
EP2039369A1 (fr) 2009-03-25
SI1737488T1 (sl) 2009-08-31
WO2005102386A1 (fr) 2005-11-03
RU2380116C2 (ru) 2010-01-27
ES2322171T3 (es) 2009-06-17
TNSN06339A1 (en) 2008-02-22
EP1737488A1 (fr) 2007-01-03
DE602005013197D1 (de) 2009-04-23
KR20080024944A (ko) 2008-03-19
CY1109121T1 (el) 2014-07-02
HRP20090261T1 (hr) 2009-07-31

Similar Documents

Publication Publication Date Title
CL2004001174A1 (es) Composicion farmaceutica que comprende: 1-(4-fluorofenil)-3(r)-[3-(4-fluorofenil)-3(s)-hidroxipropil]-4(s)-(4-hidroxifenil)-2-acetidinona (ezetimiba) y excipientes; y su uso en el tratamiento y/o prevencion de aterosclerosis, hipercolesterolemia, dia
CY1110783T1 (el) Μονοκλωνικα αντισωματα κατα αυξητικου παραγοντα ηπατοκυτταρων
CY1110188T1 (el) Αντισωματα κατα συζυγων φωσφορυλχολινης
MA31899B1 (fr) Anticorps monoclonaux qui se lient au hgm-csf et compositions medicales les comprenant
EP2371389A3 (fr) Anticorps spécifiques au FcgammaRIIB et procédés d'utilisation associés
WO2006033700A3 (fr) Composition d'anticorps anti-her2
CY1112277T1 (el) ΑΝΘΡΩΠΟΠΟΙΗΜΕΝΟΙ ΑΝΤΑΓΩΝΙΣΤΕΣ ΑΝΤΙ-β7 ΚΑΙ ΧΡΗΣΕΙΣ ΑΥΤΩΝ
CY1113224T1 (el) Νεο αντισωμα αντι-ρlgf
CY1111622T1 (el) Ανθρωποποιημενοι ανταγωνιστες anti-cmet
ATE419872T1 (de) Vorbeugende und therapeutsche monoklonale antikörper gegen vacciniavirusantigene
WO2006065553A3 (fr) Vaccins glycoconjugues contenant un peptidoglycane
GB0008305D0 (en) Treatment of fungal infections
WO2002075274A3 (fr) Methode et trousse pour le suivi des maladies neurodegeneratives
EP1542721A4 (fr) Anticorps "s" modifies
EP1411962A4 (fr) Traitement par anticorps monoclonal du cancer du pancreas
ATE395931T1 (de) Polysaccharid-impfstoff gegen staphylokokken infektionen
DE60141297D1 (de) Gegen das menschliche bst2 antigen gerichteter monoklonaler antikörper
CY1109121T1 (el) Θεραπεια μυκητιασικων μολυνσεων
WO2006137938A3 (fr) Fragments d'anticorps assurant la protection contre l'infection par des pathogenes, methodes d'utilisation de ces derniers
WO2022235867A3 (fr) Anticorps neutralisant anti-sars-cov-2 et leurs procédés d'utilisation
WO2003097082A3 (fr) Traitement de la maladie de crohn ou du psoriasis a partir d'anticorps anti-interferon gamma
AR055072A1 (es) Uso de anticuerpos anti- madcam para el tratamiento de enfermedad celiaca y esprue tropical
WO2002096455A3 (fr) Utilisation d'immunoglobulines polyclonales
WO2002090542A8 (fr) Epitopes antigenes du factor viii, inhibiteurs diriges contre ces epitopes et leur utilisation
UA98756C2 (ru) Антитело, которое связывается с cd38, для лечения заболевания, опосредованного cd38